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ABSTRACT
Objective To determine the efﬁcacy of acotiamide, an
acetylcholinesterase inhibitor, in patients with functional
dyspepsia (FD) in a 4-week trial
Methods A multicentre, randomised, placebo-
controlled, parallel-group, phase III trial was carried out,
in which patients with FD received 100 mg of acotiamide
or placebo three times a day for 4 weeks, with 4 weeks
post-treatment follow-up. The primary efﬁcacy end
points were global assessment of overall treatment
efﬁcacy (OTE) and elimination rate of all three meal-
related symptoms (postprandial fullness, upper
abdominal bloating and early satiation), as derived from
daily diaries. Secondary efﬁcacy end points were
individual symptom scores and quality of life. Adverse
events were monitored.
Results 52.2% of those receiving acotiamide and 34.8%
in the placebo group (p<0.001) were classiﬁed as
responders according to a global assessment of OTE.
Over 4 weeks, the elimination rate for all three meal-
related symptoms was 15.3% among patients receiving
acotiamide compared with 9.0% in the placebo group
(p¼0.004). The signiﬁcant beneﬁt of acotiamide over
placebo in OTE and elimination rate was maintained
during the 4 week post-treatment follow-up. All other
secondary efﬁcacy end points, including quality of life,
were signiﬁcantly improved with 100 mg of acotiamide
as compared with placebo. The number needed to treat
was 6 for OTE and 16 for symptom elimination rate. The
incidence of adverse events was similar between the
acotiamide group and placebo group and no signiﬁcant
cardiovascular effects due to treatment were seen.
Conclusions Over 4 weeks, acotiamide signiﬁcantly
improved symptom severity and eliminated meal-related
symptoms in patients with FD.
Trial registration number http://ClinicalTrials.gov
number, NCT00761358.
INTRODUCTION
Dyspeptic symptoms, deﬁned as the presence of
symptoms considered to originate from the
gastroduodenal region, occur commonly in the
general population.
1 2 Epidemiological surveys
suggest that 20e30% of the general population has
dyspepsia over the course of a year and this
percentage is reasonably consistent around the
world.
2 In Japan, about 25.6% of the population
report dyspeptic symptoms.
23In most of these
subjects, additional examinations fail to identify
a cause for the symptoms and this is referred to as
functional dyspepsia (FD).
45According to the Rome
III consensus, FD is deﬁned as the presence of
symptoms thought to originate in the gastroduo-
denal region (postprandial fullness, early satiation,
epigastric pain or burning), in the absence of any
organic, systemic or metabolic disease that might
explain the symptoms. FD has considerable impact
on quality of life (QoL), healthcare use and loss of
productivity.
6
The underlying pathophysiology in FD is
incompletely understood, possibly because of the
heterogeneous nature of the disorder.
1 7 Based on
a presumed relationship between symptom
pattern and underlying pathophysiological mech-
anisms, the Rome III consensus subdivided FD into
two subcategories: postprandial distress syndrome
(PDS) and epigastric pain syndrome.
1 PDS; char-
acterised by postprandial fullness and early satia-
tion, is also referred to as meal-related FD, and is
thought to be caused by disturbed gastric motor
function.
178It has been suggested that this group
of patients may respond to drugs that alter gastric
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Signiﬁcance of this study
What is already known on this subject?
< In phase II trials in Europe, the USA and Japan,
acotiamide has been shown to have beneﬁcial
effects in functional dyspepsia (FD), particularly
for meal-related FD symptoms such as post-
prandial fullness, upper abdominal bloating and/
or early satiation, without major adverse events.
What are the new ﬁndings?
< Acotiamide was better than placebo in
improving overall treatment efﬁcacy and meal-
related symptoms and this beneﬁt started during
the second week of treatment.
< Acotiamide achieved a higher rate of elimination
of meal-related FD symptoms, which was
associated with signiﬁcant improvement in all
subdomains of the disease-speciﬁc Short Form-
Nepean Dyspepsia Index (SF-NDI) quality-of-life
assessment.
How might it impact on clinical practice in the
foreseeable future?
< FD is one of the most common disorders seen in
clinical practice, and there are no treatments of
established efﬁcacy.
< The ﬁndings will assist many clinicians seeing
dyspeptic patients in general and specialised
practice.
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Neurogastroenterologymotility, such as prokinetic and fundus-relaxing drugs, but to
date no drug has been approved for the treatment of FD or
PDS.
178
Acotiamide (Z-338) is a ﬁrst-in-class drug which exerts
gastroprokinetic activity by enhancement of acetylcholine
release.
8 9 It does so by acting as an antagonist on muscarinic
autoreceptors in the enteric nervous system and by inhibiting
cholinesterase activity.
9e11 Acotiamide may act directly on the
gut and also indirectly through the brainegut axis via actions in
the central nervous system.
12 In animal models and in man,
acotiamide enhances gastric emptying and gastric accommoda-
tion, two factors which have been implicated in the pathogenesis
of PDS symptoms.
8e11 In a rat model, acotiamide reversed stress-
induced inhibition of gastric emptying and food intake.
12 In phase
II trials in Europe, the USA and Japan, acotiamide has been
shown to have beneﬁcial effects in FD, particularly for meal-
related FD symptoms such as postprandial fullness, upper
abdominal bloating and/or early satiation, without major adverse
events.
13e16 Based on the Japanese and European studies, 100 mg
three times a day was identiﬁed as the most effective dose.
13 14
In the present phase III, placebo-controlled trial, we aimed to
determine the efﬁcacy, safety and effect on QoL of oral acotia-
mide at a dose of 100 mg three times a day for 4 weeks, in
patients with FD as deﬁned by the Rome III classiﬁcation.
1
METHODS
Study design
This multicentre, randomised, double-blind, placebo-controlled,
parallel-group, phase III trial was conducted at 67 centres in
Japan over a period of 21 months, from October 2008 to June
2010. For all evaluations, patients were asked to attend the
centres after having fasted in the morning. The study design is
summarised in ﬁgure 1.
The trial was conducted in accordance with the Good Clinical
Practice Guidelines of the International Conference on Harmo-
nisation of Technical Requirements for Registration of Pharma-
ceuticals for Human Use, the Declaration of Helsinki and local
laws and regulations. The protocol was reviewed and approved
by the ethics committees of participating centres. Written
informed consent was obtained from every patient.
Eligibility of patients
We recruited Japanese patients with FD aged between 20
and 64 years, who had FD-PDS as deﬁned by the Rome III
classiﬁcation.
1
In agreement with the Rome III PDS deﬁnition, patients were
included if they had had postprandial fullness or early satiation
for at least 6 months before inclusion. Patients were also eligible
if they had had two or more of the following symptoms at
a moderate or severe level within the previous 3 months: upper
abdominal pain, upper abdominal discomfort, postprandial
fullness, upper abdominal bloating, early satiation, nausea,
vomiting or excessive belching. Patients were not necessarily
excluded if they had coexisting epigastric pain syndrome
symptoms (epigastric pain, epigastric burning), but the
symptom causing the most distress at the time of obtaining
informed consent had to be one of the following meal-related
symptoms: postprandial fullness, upper abdominal bloating or
early satiation. All patients underwent upper abdominal
endoscopy in the screening period. Those with any changes in
the oesophagus, duodenum or in the stomach were excluded.
Patients who had experienced heartburn within 12 weeks before
the baseline period were excluded. Patients with the comorbidity
irritable bowel syndrome were excluded. Helicobacter pylori status
was not assessed as part of the study.
The following exclusion criteria were also applied: presence of
any symptom indicating serious or malignant disease, drug or
alcohol abuse and severe abnormality in the electrocardiogram at
rest or the clinical or laboratory examination during the baseline
period. Anti-secretory drugs, antacids, prokinetics, non-steroidal
anti-inﬂammatory drugs and antidepressant drugs were not
allowed after the baseline period. Pregnant or breastfeeding
women and those of childbearing age who were not using an
approved method of contraception were also excluded.
Randomisation
The 4-week treatment period was preceded by an 8-day baseline
period after the screening visit and followed by a 4-week post-
treatment follow-up period. Before undergoing randomisation at
the end of the baseline period, patients had symptoms evaluated
each week during the baseline period. Randomisation was
performed with a computer-generated program. At the end of
the baseline period, eligible patients were assigned a random-
isation number according to a predetermined list at each centre.
These numbers were allocated in sequential order and registered
in the patient enrolment list and the allocation was concealed.
Emergency envelopes containing the randomisation code were
provided to the investigators and were examined at the end of
the trial to ensure that the trial blinding had been maintained.
Assessments
No universally accepted end point has been established for
therapeutic trials in FD and the Food and Drug Administration
(FDA) has provided no speciﬁc guidelines.
17 A well-recognised
Figure 1 Trial design. Daily dose:
three times a day before meal.
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Neurogastroenterologyapproach is the assessment of global outcome by the ‘overall
treatment effect’ (OTE) approach, where the patients is asked at
intervals during, or at completion of the treatment, whether
symptoms have remained the same, improved or deteriorated
compared with pretreatment phase.
17 18 The advantage of this
end point is that it closely resembles the way in which doctors
evaluate treatment beneﬁt in clinical practice, but it does imply
recall of pretreatment symptom severity. OTE has been used as
a secondary outcome measure in several therapeutic trials in
FD.
19e23 OTE was used most recently in the tegaserod FD
studies, where a weekly global assessment of change was rated
on a seven-point Likert scale and this end point generated the
most consistent improvements with tegaserod over placebo.
24
For our phase III study, OTE was evaluated weekly and
severity ratings of individual symptoms were obtained in daily
diaries using Likert scales. QoL was assessed using a validated
scale.
25 26
Symptoms and global assessment
During the 8-day baseline period, the 4-week treatment period
and the 4-week post-treatment follow-up period, patients rated
each of nine symptoms (upper abdominal pain, upper abdominal
discomfort, postprandial fullness, upper abdominal bloating,
early satiation, excessive belching, nausea, vomiting and heart-
burn) on a severity scale of 0e3 (none, mild, moderate and
severe) using paper diaries. Each week, patients completed
a global assessment of the OTE questionnaire. The question
asked was ‘How were your gastric symptoms during the past
week in comparison with the baseline period?’. This was scored
in the paper diaries on a seven-point Likert scale, ranging from
‘extremely improved compared with the baseline period’,
‘improved compared with the baseline period’, ‘slightly improved
compared with the baseline period’, ‘not changed’, ‘slightly
aggravated compared with the baseline period’, ‘aggravated
compared with the baseline period’ and ‘extremely aggravated
compared with the baseline period’.
Primary efﬁcacy end points
The two primary efﬁcacy end points were OTE and elimination
rate of all three cardinal symptoms: postprandial fullness, upper
abdominal bloating and early satiation (no symptoms) at the
last survey point.
Disease-speciﬁc QoL
To assess the effects of treatment on validated disease-speciﬁc
QoL, the Japanese version of the Short Form-Nepean Dyspepsia
Index questionnaire (SF-NDI)
25 26 was used at baseline, at week
4 of treatment and week 4 of the post-treatment follow-up
period. Data for 10 items were obtained and consisted of ﬁve
subscales: tension, interference with daily activities, eating/
drinking, knowledge/control and work/study. The scores ranged
from 1 to 5, with lower scores indicating a better QoL.
Safety assessments
Data from patients who took at least one dose of the trial drug
were included in the full analysis set (FAS) and safety popu-
lation. Adverse events were reported at weeks 2 and 4 of
treatment and week 4 of the post-treatment follow-up period.
Vital signs were evaluated at the baseline visit, at week 4 of
treatment and week 4 of the post-treatment follow-up period.
Results of electrocardiography, clinical laboratory tests and
physical examinations were evaluated at the baseline visit, at
week 4 of treatment and at week 4 of the post-treatment
follow-up period.
Statistical analysis
Based on our previous phase IIb trials, the proportions of the
acotiamide and placebo responders for OTE were expected to be
50% and 40%. For elimination of all the three symptoms,
proportions were expected to be 20% and 10%, respectively. The
two-sided signiﬁcance level was 0.05. A sample size of 820 (410
patients in each arm) was estimated to have at least 80% power
to detect the differences. The power was calculated as the
product of the power of each end point, 81.7%, 98.0%.
The efﬁcacy analysis was based on both the FAS and per
protocol (PP) populations. Adverse effects were evaluated in the
safety population.
For evaluation of the primary end point, patients who were
“extremely improved” or “improved” on the OTE scale were
considered responders. The elimination rate was the proportion of
patients who achieved elimination of all three symptomsdthat
is, postprandial fullness, upper abdominal bloating and early
satiation. Primary efﬁcacy variables were evaluated over the entire
treatment period using Fisher’s exact test method. The level of
signiﬁcance was set at 0.05 (two sided).
A frequency distribution table was prepared for the OTE at
the last survey point and improvement rates were determined
from this. Treatment effects and 95% CIs were obtained for each
variable.
Recently and well after the design and start of this phase III
study, the FDA issued a statement on the use of patient-reported
outcome measures in the evaluation of therapeutic efﬁcacy of
drugs for medical conditions, in general, and irritable bowel
syndrome, in particular.
27 28 In these documents, the FDA no
longer recommends overall symptom assessment in binary
questions, or in comparison with a previous time points, but
advocates assessment of the severity of individual clinically
important symptoms and deﬁning responders on the basis of
a clinically meaningful improvement of these symptoms.
28 In
the absence of an existing validated instrument for FD and in
order to allow better estimation of the magnitude of the ther-
apeutic response to acotiamide, we performed a post hoc
responder analysis on changes in severity of individual symp-
toms. For each symptom, a responder was deﬁned as a patient
with a more than 50% reduction in symptom severity during the
last observation week in comparison with baseline severity
(weekly average), as derived from the daily diaries.
RESULTS
Enrolment and baseline characteristics of the patients
We screened 1394 outpatients with a suspected diagnosis of
patients with FD (ﬁgure 2) and of these, 497 were excluded
during the baseline period. The remaining 897 patients were
randomly assigned to receive one of two trial drugs: 100 mg of
acotiamide (452 patients) or placebo (445 patients) three
times a day. Five patients withdrew from the trial, thus, 892
patients were included in the FAS. The baseline characteris-
tics of the trial population were similar between the groups
(table 1).
Primary efﬁcacy end point
The responder rate based on the OTE at the last survey point on
FAS was 52.2% for patients receiving acotiamide and 34.8% with
placebo (p<0.001, table 2).
The elimination rate of all three meal-related symptoms
(postprandial fullness, upper abdominal bloating and early sati-
ation) at the last survey point on FAS was 15.3% with acotia-
mide and 9.0% with placebo (p¼0.004, table 2).
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PP analysis
The PP analysis of OTE data at the last survey point showed
similar response rates of 53.3% with acotiamide group and
34.7% with placebo group (p<0.001). Moreover, the elimination
rate of all of the three symptoms at the last survey point on PP
was 15.2% with acotiamide and 9.0% with placebo (p¼0.006).
Elimination rate of individual symptoms
Signiﬁcantly higher elimination rates were obtained with acotia-
mide than with placebo for early satiation and for postprandial
fullness (table 2). The highest elimination rate was seen for early
satiation with acotiamide (37.8% vs 25.4% with placebo,
p<0.001) (table 2).
Weekly evaluations on FAS
For OTE, a signiﬁcant difference became apparent from week 2
(ﬁgure 3). For the elimination rate of all of the three symptoms,
there was a signiﬁcant difference from week 3 (ﬁgure 4). After
discontinuing acotiamide or placebo, neither group returned to
Figure 2 Summary of patient ﬂow.
FAS, full analysis set.
Table 1 Baseline characteristics of the patients receiving at least one
dose of study medication (full analysis set)
Characteristics Placebo Acotiamide
Patients (n) 442 450
Age (years), mean6SD 37.169.9 37.6610.7
Sex (n (%))
Female 255 (57.7) 274 (60.9)
Male 187 (42.3) 176 (39.1)
Height (cm), mean6SD 164.1368.85 163.2768.59
Weight (kg), mean6SD 60.14612.46 59.23612.20
Most bothersome symptom
(n (%))
Postprandial fullness 273 (61.8) 281 (62.4)
Upper abdominal bloating 86 (19.5) 72 (16.0)
Early satiation 83 (18.8) 97 (21.6)
Table 2 Efﬁcacy end points (full analysis set)
End point
Placebo
(n[442)
Acotiamide
(n[450) p Value
Primary end point
Overall treatment efﬁcacy 34.8 52.2 <0.001
Elimination rate for all three
symptoms
9.0 15.3 0.004
Secondary end point
Elimination rate of individual symptoms at last survey point
Postprandial fullness 16.6 22.7 0.026
Upper abdominal
bloating
28.5 34.5 0.084
Early satiation 25.4 37.8 <0.001
Patients achieving the two primary overall efﬁcacy end points: “extremely improved” or
“improved” were considered responders.
Elimination rate: the proportion of patients who achieved elimination of all of the three
symptoms: postprandial fullness, upper abdominal bloating and early satiation (no
symptoms) at the last survey point.
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A signiﬁcantly higher response rate persisted in the acotiamide
group compared with the placebo group for all 4-week post-
treatment follow-up periods (all p<0.005).
Individual symptom scores for postprandial fullness, upper
abdominal bloating and early satiation were signiﬁcantly
improved in the acotiamide group compared with the placebo
group. The improvement of symptom scores for upper abdom-
inal pain, upper abdominal discomfort, nausea, vomiting and
excessive belching did not differ signiﬁcantly between the
groups at the last survey point.
The number needed to treat (NNT)
For the interpretation of treatment efﬁcacy, the NNT was an
important measure to compare the different therapeutic options
for an FD. Based on the results, the NNT as indicated by OTE
was calculated as 6 and the NNT for the elimination rate of all
of the three symptoms at the end of the treatment period were
calculated as 16.
Post hoc analysis of individual symptom severities
When a decrease in symptom severity of >50% was considered,
the responder rates for postprandial fullness, early satiation, upper
abdominal pain and upper abdominal bloating were signiﬁcantly
higher during acotiamide treatment than with placebo (table 3).
For the meal-related symptoms of postprandial fullness, early
satiation and upper abdominal bloating, the responder difference
over placebo ranged between 11.8% and 19.2%.
Quality-of-life scores
Overall SF-NDI scores at the last observation in the FAS showed
a signiﬁcantly greater improvement from baseline among the
patients with acotiamide ( 3.66) than among those with
placebo ( 2.84) (p<0.001). Similarly, all ﬁve SF-NDI subscale
scores at the last observation showed improvements from
baseline in the acotiamide group compared with the placebo
group (table 4).
Safety
Adverse events were reported by 252 of the 450 patients (56.0%)
receiving acotiamide and 267 of the 442 patients (60.4%) with
placebo. The most commonly reported adverse events were
increase of serum triglycerides, serum prolactin, or serum
g-glutamyltransferase and nasopharyngitis (table 5). Most
adverse effects were mild or moderate in severity. No deaths
occurred during the trial. Only one serious adverse event was
reported: an intervertebral disc herniation occurred in one of the
450 patients (0.2%) treated with acotiamide, judged as ‘not
related’. No serious adverse events were reported in the 442
patients receiving placebo.
DISCUSSION
Despite its high prevalence and impact, treatment options for
FD are limited. Systematic reviews of the available literature
indicate that antisecretory drugs and prokinetic agents may be
better than placebo in relieving symptoms of FD,
19 20 but the
studies were hampered by ﬂaws in patient selection and trial
design.
18 21e23 29e31 No treatment has been approved for FD.
Proton pump inhibitors are mainly effective in patients with
Figure 3 Weekly improvement rate in overall treatment efﬁcacy.
***p<0.005 compared with placebo. FW, follow-up week after
treatment; W, week.
Figure 4 Elimination rate for all three symptoms. *p<0.05 compared
with placebo. ***p<0.005 compared with placebo. FW, follow-up week
after treatment; W, week.
Table 3 Responder rates for individual symptoms: (average symptom
score at the last observation period)/(average symptom score at
baseline) &0.5
Symptom Group N
Responder
rate (%) p Value
Upper abdominal
pain
Placebo 442 60.7 e
Acotiamide 450 70.1 0.038
Upper abdominal
discomfort
Placebo 442 58.1 e
Acotiamide 450 64.8 0.080
Postprandial fullness Placebo 442 47.3 e
Acotiamide 450 66.5 <0.001
Upper abdominal
bloating
Placebo 442 57.1 e
Acotiamide 450 68.9 0.001
Early satiation Placebo 442 56.8 e
Acotiamide 450 69.1 <0.001
Nausea Placebo 442 74.4 e
Acotiamide 450 79.8 0.373
Vomiting Placebo 442 90.2 e
Acotiamide 450 89.3 1.000
Excessive belching Placebo 442 66.9 e
Acotiamide 450 67.7 0.904
Table 4 Summary of overall and subscale symptom scores on the
Short Form-Nepean Dyspepsia Index (SF-NDI) questionnaire
Variable
Change from baseline SF-NDI (score),
mean±SD
p Value Placebo (n[442) Acotiamide (n[450)
Overall symptom score  2.8463.56  3.6663.38 <0.001
Tension  0.5760.87  0.7360.84 0.006
Interference with daily
activities
 0.4860.87  0.6260.85 0.016
Eating/drinking  0.6660.90  0.8560.87 0.001
Knowledge/control  0.6160.89  0.7960.86 0.002
Work/study  0.5160.89  0.6760.85 0.007
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Neurogastroenterologysymptoms of heartburn and FD, but they have limited efﬁcacy
compared with placebo when the patients’ symptoms are not
acid-related.
29 30 32 33 Attempts to establish efﬁcacy for proki-
netic drugs in FD have been disappointing. Mosapride, a 5-HT4
receptor agonist, was no better than placebo in a dose-ﬁnding
trial in FD.
34 Positive results were obtained in a phase IIb trial
with itopride, a dopamine-2 receptor antagonist with cholines-
terase inhibitory properties, but in two phase III trials the drug
was no better than placebo.
35 36 Tegaserod, another 5-HT4
agonist, showed some promise after phase II studies,
37 but the
result of two phase III trials was disappointing.
24 Therefore,
a true unmet medical need for FD exists and many patients turn
to alternative treatments of unproven value.
38
Acotiamide is a ﬁrst-in-class drug that was developed for the
treatment of FD and other upper gastrointestinal symptomatic
conditions. Placebo-controlled phase II studies in Europe and in
Japan showed beneﬁcial effects of acotiamide for FD symptoms
of postprandial fullness, upper abdominal bloating and early
satiation.
13 14 The analysis of the Japanese phase II studies
showed that acotiamide had signiﬁcant beneﬁt in comparison
with placebo using OTE as a primary end point in a post hoc
analysis of patients who fulﬁlled Rome III criteria for PDS. In
the Japanese studies, a higher elimination rate of meal-related
symptoms was also seen with acotiamide, and 100 mg three
times a day was established as the optimal dose.
13 In a phase II
trial in the USA, the randomised treatment phase was preceded
by an open-label proton pump inhibitor (PPI) trial to eliminate
PPI responders. In the 12-week double-blind, placebo-controlled
treatment phase, using OTE, acotiamide showed signiﬁcant
efﬁcacy over placebo in the PDS group, with the highest beneﬁt
occurring during the ﬁrst 4 weeks. In addition, the beneﬁcial
effects were conﬁrmed using adequate relief for >50% of the
time as the end point. Furthermore, acotiamide showed signiﬁ-
cant improvement in several domains of the generic Short Form-
36 QoL scale and in three of ﬁve domains in the SF-NDI.
25 26
In this phase III randomised, 4-week placebo-controlled trial,
patients who fulﬁlled the Rome III criteria for FD-PDS were
enrolled and both primary end points were met. A signiﬁcantly
higher rate of patients achieved the ﬁrst primary end
pointdnamely, improved or extremely improved on the OTE, in
the acotiamide group than in the placebo group. OTE evaluation
allows the individual to integrate all aspects of his condition into
a single treatment outcome. OTE has previously been used as an
outcome measure in studies evaluating H. pylori eradication or
acid suppression in FD.
18 21e23 29e31 More recently, OTE was
used in the tegaserod FD studies, where this end point generated
the most consistent improvements with tegaserod over
placebo.
24 37 The advantage of this end point is that it closely
resembles the way in which doctors evaluate treatment beneﬁt
in clinical practice. The bidirectional construct makes it partic-
ularly suitable for evaluating symptom improvement and also
deterioration. Psychometric analysis supports the concept that
a rating of ‘improved’ or ‘extremely improved’ on the OTE
indicates substantial and clinically meaningful improvement.
31
Moreover, with a margin of more than 17% over placebo in
reaching this end point and a NNT of 6, the beneﬁt of acotia-
mide is well above the minimal range of efﬁcacy that was
proposed to be clinically relevant by a group of experts.
39 On the
other hand, because of the inherent recall, which may lead to
bias, the FDA has recently argued against the use of OTE in
future drug development trials.
28 However, the clinical relevance
of the improvement with acotiamide is further supported by the
signiﬁcant improvement of several prespeciﬁed secondary efﬁ-
cacy end points, including disease-related QoL. For the latter, the
changes seen using the SF-NDI were of the order of 1 SD or 10%
of the total scale range on all ﬁve domains and are above the
minimal clinically relevant difference.
40 The post hoc analysis of
responder rates for individual symptoms, using a 50% decrease
during the last evaluation week compared with baseline, further
conﬁrms substantial beneﬁt of acotiamide over placebo, espe-
cially for meal-related symptoms.
The other primary end point, elimination of all of three meal-
related symptoms, was also reached by signiﬁcantly more
patients in the acotiamide group than in the placebo group.
Acotiamide was better than placebo in eliminating symptoms of
postprandial fullness and upper abdominal bloating, but the
margin over placebo at the end of the 4-week trial was modest,
with an estimated NNTof 16. More robust efﬁcacy in symptom
resolution was seen for early satiation (37.8% vs 25.4% with
acotiamide and placebo, p<0.001). The elimination rate of all
three symptoms was also signiﬁcantly higher for acotiamide
than with placebo at the last survey point and further increased
during the 4-week post-treatment week. Gradual symptom
improvement over the 4-week treatment period was seen in
both arms, but acotiamide showed a higher rate of improve-
ment, and signiﬁcantly better responses on OTE were already
reached in week 2. Moreover, the efﬁcacy over placebo persisted
during the 4 weeks after the end of the treatment period and
there were no signs of immediate relapse or rebound symptom
aggravation. Both the rapid onset of efﬁcacy and the lack of
rapid relapse upon interruption of treatment are attractive
aspects when considering the use of acotiamide in clinical
practice.
Similar to previous studies,
13e16 acotiamide was well tolerated
and the incidences of adverse events were similar between the
acotiamide group and placebo group. Furthermore, no clinically
relevant changes in vital signs or electrocardiographic variables
were obtained. A number of drugs that have been used or were
under development for the treatment of FD, such as cisapride or
tegaserod, have been associated with major cardiovascular side
effects.
41 42 Afﬁnities of these drugs for the HERG channel or for
5-HTreceptors have been implicated in the occurrence of major
cardiovascular events.
43 Acotiamide has little or no afﬁnity for
these receptors, which contributes to its favourable beneﬁterisk
proﬁle, and thorough QTc studies in the USA with acotiamide
up to 900 mg showed no arrhythmogenic potential.
Strengths of the study are the large number of patients
studied and the multicentre double-blind, placebo-controlled
design. Limitations are the short treatment duration of only
4 weeks for a condition which is often chronic relapsing, but
this study duration was chosen in agreement with the regula-
tory authorities in Japan. The study does not examine efﬁcacy
Table 5 Incidence of adverse events (>4% in any group)
Adverse drug reaction
Number of adverse events (%)
Placebo
(n[442)
Acotiamide
(n[450)
Serum triglycerides increased 91 (20.6) 85 (18.9)
Serum prolactin increased 30 (6.8) 21 (4.7)
Serum bilirubin increased 18 (4.1) 19 (4.2)
Serum g-glutamyltransferase increased 28 (6.3) 32 (7.1)
Serum alanine aminotransferase
increased
17 (3.8) 18 (4.0)
White blood cell count increased 21 (4.8) 14 (3.1)
Diarrhoea 18 (4.1) 21 (4.7)
Nasopharyngitis 41 (9.3) 39 (8.7)
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ever, the post-treatment follow-up period does not show
rebound tachyphyllaxis but, on the contrary, shows sustained
symptomatic beneﬁt. Future studies will need to examine the
relapse rate over longer post-treatment periods and the response
to re-treatment.
The mechanism underlying the clinical beneﬁts e e nw i t h
acotiamide in FD-PDS is incompletely elucidated and may well
be multifactorial. Animal studies have shown that acotiamide
can enhance the gastric emptying rate, and meal-induced
gastric accommodation and impaired accommodation as well as
delayed gastric emptying have been established as key patho-
physiological mechanisms in FD.
12 Mechanistic studies in
patients with FD have conﬁrmed the ability of acotiamide to
enhance gastric accommodation and to enhance gastric
emptying, and these may be particularly relevant in the
improvement of symptoms of early satiation and postprandial
fullness.
44 In addition, many patients with FD have increased
anxiety levels, which are associated with decreased gastric
compliance and enhanced gastric sensitivity in patients with
FD and in healthy controls.
45 46 In an animal model, acotiamide
pretreatment inhibited the expression of central mediators of
induced stress (neuromedin U and BDNF) and the associated
delayed gastric emptying and feeding inhibition.
12
In conclusion, in this 4-week randomised placebo-controlled
phase III trial, acotiamide was effective, safe and well tolerated
in the treatment of patients with FD-PDS according to the
Rome III diagnostic criteria. Acotiamide 100 mg three times
a day was better than placebo in improving OTE and meal-
related symptoms and this beneﬁt became apparent during the
second week of treatment. Acotiamide achieved a higher rate of
elimination of meal-related FD symptoms and this was associ-
ated with signiﬁcant improvement on all subdomains of the
disease-speciﬁc SF-NDI QoL assessment. When treatment was
stopped, no rapid symptom relapse or rebound occurred. Taking
into account the favourable tolerability and safety proﬁle in this
and previous studies, acotiamide is a drug for the treatment of
FD, a highly prevalent condition for which there is no treatment
with established or approved efﬁcacy.
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